EE05294B1 - TALL-1-ga seostuv ainekompositsioon - Google Patents

TALL-1-ga seostuv ainekompositsioon

Info

Publication number: EE05294B1
Authority: EE; Estonia
Prior art keywords: tall; seq; domain; matter; vehicle
Prior art date: 2001-05-11

Application number

EEP200300552A

Other languages

English (en)

Estonian (et)

Inventor

Min Hosung

Hsu Hailing

Xiong Fei

Original Assignee

Amgen Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-11

Filing date

2002-05-13

Publication date

2010-04-15

2002-05-13 Application filed by Amgen Inc. filed Critical Amgen Inc.

2004-02-16 Publication of EE200300552A publication Critical patent/EE200300552A/xx

2010-04-15 Publication of EE05294B1 publication Critical patent/EE05294B1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
Plant Pathology (AREA)
Crystallography & Structural Chemistry (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Virology (AREA)
Oncology (AREA)
Hematology (AREA)
Transplantation (AREA)
Dermatology (AREA)

EEP200300552A 2001-05-11 2002-05-13 TALL-1-ga seostuv ainekompositsioon EE05294B1 (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US29019601P	2001-05-11	2001-05-11
PCT/US2002/015273 WO2002092620A2 (en)	2001-05-11	2002-05-13	Peptides and related molecules that bind to tall-1

Publications (2)

Publication Number	Publication Date
EE200300552A EE200300552A (et)	2004-02-16
EE05294B1 true EE05294B1 (et)	2010-04-15

Family

ID=23114926

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200300552A EE05294B1 (et)	2001-05-11	2002-05-13	TALL-1-ga seostuv ainekompositsioon

Country Status (30)

Country	Link
US (5)	US7259137B2 (xx)
EP (4)	EP2292655B1 (xx)
JP (1)	JP4516719B2 (xx)
KR (1)	KR100902687B1 (xx)
CN (3)	CN1970077A (xx)
AT (2)	ATE549354T1 (xx)
AU (1)	AU2002342669C1 (xx)
BG (1)	BG66270B1 (xx)
BR (1)	BR0209546A (xx)
CA (1)	CA2446189C (xx)
CY (1)	CY1107131T1 (xx)
CZ (1)	CZ304592B6 (xx)
DE (1)	DE60222882T2 (xx)
DK (1)	DK1385882T3 (xx)
EA (1)	EA010435B1 (xx)
EE (1)	EE05294B1 (xx)
ES (3)	ES2387546T3 (xx)
HK (1)	HK1207390A1 (xx)
HU (1)	HU229910B1 (xx)
IL (2)	IL158719A0 (xx)
MX (1)	MXPA03010210A (xx)
NO (1)	NO331785B1 (xx)
NZ (2)	NZ529267A (xx)
PL (2)	PL393317A1 (xx)
PT (1)	PT1385882E (xx)
RS (1)	RS51708B (xx)
SI (1)	SI1385882T1 (xx)
SK (1)	SK288175B6 (xx)
WO (1)	WO2002092620A2 (xx)
ZA (1)	ZA200308513B (xx)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6812327B1 (en) *	1996-10-25	2004-11-02	Human Genome Sciences, Inc.	Neutrokine-alpha polypeptides
US8212004B2 (en)	1999-03-02	2012-07-03	Human Genome Sciences, Inc.	Neutrokine-alpha fusion proteins
US7879328B2 (en) *	2000-06-16	2011-02-01	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to B lymphocyte stimulator
KR20120053525A (ko) *	2000-06-16	2012-05-25	캠브리지 안티바디 테크놀로지 리미티드	면역특이적으로 ＢＬｙＳ에 결합하는 항체
WO2002016411A2 (en) *	2000-08-18	2002-02-28	Human Genome Sciences, Inc.	Binding polypeptides and methods based thereon
DE60140773D1 (de)	2000-08-18	2010-01-21	Dyax Corp	Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS)
UA83458C2 (uk)	2000-09-18	2008-07-25	Байоджен Айдек Ма Інк.	Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
CN1970077A (zh) *	2001-05-11	2007-05-30	安姆根有限公司	与tall－1结合的肽和相关分子
US7112410B1 (en)	2001-08-29	2006-09-26	Human Genome Sciences, Inc.	Human tumor necrosis factor TR21 and methods based thereon
MXPA05007019A (es)	2002-12-30	2005-08-18	Amgen Inc	Terapia de combinacion con factores co-estimuladores.
WO2004094620A2 (en)	2003-03-28	2004-11-04	Biogen Idec Ma Inc.	Truncated baff receptors
EP1629001A2 (en)	2003-06-05	2006-03-01	Genentech, Inc.	Blys antagonists and uses thereof
US7605120B2 (en) *	2003-10-22	2009-10-20	Amgen Inc.	Antagonists of the brandykinin B1 receptor
EP1709072A1 (en)	2004-01-29	2006-10-11	Genentech, Inc.	Variants of the extracellular domain of bcma and uses thereof
US20070004658A1 (en)	2004-06-21	2007-01-04	Nick Vandeghinste	Method and means for treatment of osteoarthritis
US7442778B2 (en)	2004-09-24	2008-10-28	Amgen Inc.	Modified Fc molecules
CN100378122C (zh) *	2004-12-03	2008-04-02	中国人民解放军第三军医大学	B淋巴细胞刺激因子抑制肽及其制备方法
DE602006012839D1 (de)	2005-05-20	2010-04-22	Genentech Inc	Vorbehandlung einer biologischen probe aus einem individuum mit autoimmunkrankheit
EP1909831A4 (en)	2005-06-14	2013-02-20	Amgen Inc	SELF-BUFFING PROTEIN FORMULATIONS
US8008453B2 (en)	2005-08-12	2011-08-30	Amgen Inc.	Modified Fc molecules
KR20080074120A (ko) *	2005-10-13	2008-08-12	휴먼 게놈 사이언시즈, 인코포레이티드	자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
US9168286B2 (en) *	2005-10-13	2015-10-27	Human Genome Sciences, Inc.	Methods and compositions for use in treatment of patients with autoantibody positive disease
MY149159A (en)	2005-11-15	2013-07-31	Hoffmann La Roche	Method for treating joint damage
EP1952150B1 (en)	2005-11-23	2016-12-14	Genentech, Inc.	Methods and compositions related to b cell assays
US8211649B2 (en)	2006-03-31	2012-07-03	Human Genome Sciences, Inc.	Methods of diagnosing and prognosing hodgkin's lymphoma
US9283260B2 (en)	2006-04-21	2016-03-15	Amgen Inc.	Lyophilized therapeutic peptibody formulations
US7981425B2 (en) *	2006-06-19	2011-07-19	Amgen Inc.	Thrombopoietic compounds
WO2008051383A2 (en) *	2006-10-19	2008-05-02	Amgen Inc.	Use of alcohol co-solvents to improve pegylation reaction yields
JP5591691B2 (ja)	2007-05-22	2014-09-17	アムジエン・インコーポレーテツド	生物活性を有する融合タンパク質を作製するための組成物及び方法
EP2197421A1 (en) *	2007-08-31	2010-06-23	Amgen, Inc	Solid-state protein formulation
WO2009043049A2 (en)	2007-09-27	2009-04-02	Amgen Inc.	Pharmaceutical formulations
EP2219602A1 (en)	2007-11-15	2010-08-25	Amgen, Inc	Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
WO2010075249A2 (en)	2008-12-22	2010-07-01	Genentech, Inc.	A method for treating rheumatoid arthritis with b-cell antagonists
US20110014190A1 (en) *	2009-02-12	2011-01-20	Human Genome Sciences, Inc.	Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
CA2755336C (en)	2009-03-20	2015-07-14	Amgen Inc.	Carrier immunoglobulins and uses thereof
EP2414391B1 (en)	2009-04-02	2018-11-28	Roche Glycart AG	Multispecific antibodies comprising full length antibodies and single chain fab fragments
CA2772929A1 (en)	2009-09-03	2011-03-11	Genentech, Inc.	Methods for treating, diagnosing, and monitoring rheumatoid arthritis
US20120302737A1 (en)	2009-09-16	2012-11-29	Genentech, Inc.	Coiled coil and/or tether containing protein complexes and uses thereof
US9662271B2 (en)	2009-10-23	2017-05-30	Amgen Inc.	Vial adapter and system
TW201138821A (en)	2010-03-26	2011-11-16	Roche Glycart Ag	Bispecific antibodies
BR112012027001A2 (pt)	2010-04-23	2016-07-19	Genentech Inc	produção de proteínas heteromultiméricas
PT2575935E (pt)	2010-06-07	2015-10-20	Amgen Inc	Dispositivo de administração de medicamento
BR112013003279A2 (pt)	2010-08-13	2016-06-14	Genentech In	“métodos para tratar uma doença, método para neutralizar ou bloquear a atividade de il-1ß e/ou il-18, anticorpo, usos de um anticorpo e usos de um anticorpo monoclonal”
WO2012025530A1 (en)	2010-08-24	2012-03-01	F. Hoffmann-La Roche Ag	Bispecific antibodies comprising a disulfide stabilized - fv fragment
MX383982B (es)	2010-09-22	2025-03-14	Amgen Inc	Inmunoglobulinas portadoras y usos de las mismas.
EP2655413B1 (en)	2010-12-23	2019-01-16	F.Hoffmann-La Roche Ag	Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
BR112013019499B1 (pt)	2011-02-04	2023-01-10	Genentech, Inc.	Proteína heteromultimérica variante ou anticorpo igg modificado, método para produzir uma proteína heteromultimérica variante ou anticorpo igg modificado, composição, método para preparar uma proteína heteromultimérica e proteína heteromultimérica variante
US10689447B2 (en)	2011-02-04	2020-06-23	Genentech, Inc.	Fc variants and methods for their production
MX353143B (es)	2011-02-28	2017-12-20	Genentech Inc	Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b.
CA2831100C (en)	2011-03-31	2020-02-18	Mark Dominis Holt	Vial adapter and system
ES2926520T3 (es)	2011-04-20	2022-10-26	Amgen Inc	Aparato autoinyector
DE202012012998U1 (de)	2011-08-31	2014-06-13	Daniel Elias	Bioaktive, regenerative Mischung zur Herstellung eines Ergänzungsnahrungsmittels
HK1202878A1 (en)	2011-10-11	2015-10-09	F. Hoffmann-La Roche Ag	Improved assembly of bispecific antibodies
TR201807808T4 (tr)	2011-10-14	2018-06-21	Amgen Inc	Enjektör ve montaj yöntemi.
AR091305A1 (es)	2012-01-31	2015-01-28	Genentech Inc	ANTICUERPOS ANTI-IgE Y SUS METODOS DE USO
JP6486686B2 (ja)	2012-02-10	2019-03-20	ジェネンテック，インコーポレイテッド	単鎖抗体及び他のヘテロ多量体
WO2013148117A1 (en)	2012-03-27	2013-10-03	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
BR112014028368A2 (pt)	2012-06-27	2017-11-14	Hoffmann La Roche	método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
RU2639287C2 (ru)	2012-06-27	2017-12-20	Ф. Хоффманн-Ля Рош Аг	Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
EP3072548B1 (en)	2012-11-21	2019-03-06	Amgen, Inc	Drug delivery device
RU2704285C2 (ru)	2013-01-30	2019-10-25	Нгм Байофармасьютикалз, Инк.	Композиции и способы применения для лечения метаболических расстройств
US9161966B2 (en)	2013-01-30	2015-10-20	Ngm Biopharmaceuticals, Inc.	GDF15 mutein polypeptides
US9458246B2 (en)	2013-03-13	2016-10-04	Amgen Inc.	Proteins specific for BAFF and B7RP1
PH12022550138A1 (en)	2013-03-13	2023-03-06	Amgen Inc	Proteins specific for baff and b7rp1 and uses thereof
TWI592183B (zh)	2013-03-15	2017-07-21	安美基公司	本體輪廓可調適之自動注射器裝置
US10092703B2 (en)	2013-03-15	2018-10-09	Amgen Inc.	Drug cassette, autoinjector, and autoinjector system
EP3593839A1 (en)	2013-03-15	2020-01-15	Amgen Inc.	Drug cassette
JP6670740B2 (ja)	2013-03-22	2020-03-25	アムジエン・インコーポレーテツド	注入器および組み立て法
WO2015056356A1 (en)	2013-10-17	2015-04-23	The Nippon Synthetic Chemical Industry Co., Ltd.	Crosslinkable polymer
AU2014340174B2 (en)	2013-10-24	2019-09-12	Amgen Inc.	Drug delivery system with temperature-sensitive control
PL3060275T3 (pl)	2013-10-24	2019-12-31	Amgen Inc.	Wstrzykiwacz i sposób montażu
US10994112B2 (en)	2014-02-05	2021-05-04	Amgen Inc.	Drug delivery system with electromagnetic field generator
EP3140392B1 (en)	2014-05-06	2023-07-26	F. Hoffmann-La Roche AG	Production of heteromultimeric proteins using mammalian cells
CA3193070A1 (en)	2014-05-07	2015-11-12	Amgen Inc.	Autoinjector with shock reducing elements
EP4362039A3 (en)	2014-06-03	2024-08-07	Amgen Inc.	Controllable drug delivery system and method of use
TWI710570B (zh)	2014-07-30	2020-11-21	美商Ｎｇｍ生物製藥公司	用於治療代謝異常之組成物及方法
JP6766040B2 (ja)	2014-10-14	2020-10-07	アムジエン・インコーポレーテツド	視覚および可聴インジケータを備える薬剤注射装置
EA036985B1 (ru)	2014-10-31	2021-01-25	НДжМ БИОФАРМАСЬЮТИКАЛЗ, ИНК.	Композиции и способы лечения метаболических расстройств
CN107001482B (zh)	2014-12-03	2021-06-15	豪夫迈·罗氏有限公司	多特异性抗体
US11357916B2 (en)	2014-12-19	2022-06-14	Amgen Inc.	Drug delivery device with live button or user interface field
EP3848072A1 (en)	2014-12-19	2021-07-14	Amgen Inc.	Drug delivery device with proximity sensor
WO2016133947A1 (en)	2015-02-17	2016-08-25	Amgen Inc.	Drug delivery device with vacuum assisted securement and/or feedback
EP3261690B1 (en)	2015-02-27	2021-12-15	Amgen Inc.	Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
EP4470648A3 (en)	2015-08-13	2025-03-05	Amgen Inc.	Charged depth filtration of antigen-binding proteins
WO2017039786A1 (en)	2015-09-02	2017-03-09	Amgen Inc.	Syringe assembly adapter for a syringe
EP3386573B1 (en)	2015-12-09	2019-10-02	Amgen Inc.	Auto-injector with signaling cap
US11154661B2 (en)	2016-01-06	2021-10-26	Amgen Inc.	Auto-injector with signaling electronics
ES2814287T3 (es)	2016-03-15	2021-03-26	Amgen Inc	Reducir la probabilidad de rotura de cristal en dispositivos de administración de fármaco
IL261666B2 (en)	2016-03-31	2024-09-01	Ngm Biopharmaceuticals Inc	Binding proteins and methods of use thereof
WO2017189089A1 (en)	2016-04-29	2017-11-02	Amgen Inc.	Drug delivery device with messaging label
US11389588B2 (en)	2016-05-02	2022-07-19	Amgen Inc.	Syringe adapter and guide for filling an on-body injector
US10988284B2 (en)	2016-05-13	2021-04-27	Amgen Inc.	Vial sleeve assembly
WO2017200989A1 (en)	2016-05-16	2017-11-23	Amgen Inc.	Data encryption in medical devices with limited computational capability
WO2017209899A1 (en)	2016-06-03	2017-12-07	Amgen Inc.	Impact testing apparatuses and methods for drug delivery devices
US11285266B2 (en)	2016-07-01	2022-03-29	Amgen Inc.	Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en)	2016-08-17	2019-10-31	Amgen Inc.	Drug delivery device with placement detection
WO2018081234A1 (en)	2016-10-25	2018-05-03	Amgen Inc.	On-body injector
CA3049780A1 (en)	2017-01-17	2018-07-26	Amgen Inc.	Injection devices and related methods of use and assembly
US11752258B2 (en)	2017-02-17	2023-09-12	Amgen Inc.	Drug delivery device with sterile fluid flowpath and related method of assembly
CA3052204A1 (en)	2017-02-17	2018-08-23	Amgen Inc.	Insertion mechanism for drug delivery device
AU2018231107B2 (en)	2017-03-06	2023-04-20	Amgen Inc.	Drug delivery device with activation prevention feature
WO2018164829A1 (en)	2017-03-07	2018-09-13	Amgen Inc.	Needle insertion by overpressure
IL303449B2 (en)	2017-03-09	2024-08-01	Amgen Inc	Insertion mechanism for a drug delivery device
LT3600491T (lt)	2017-03-28	2023-10-10	Amgen Inc.	Stūmoklio koto ir švirkšto konstrukcinė sistema ir būdas
KR102198998B1 (ko)	2017-06-01	2021-01-07	서울대학교 산학협력단	신규한 항-ｃｄ40 항체 및 이의 용도
US11904143B2 (en)	2017-06-08	2024-02-20	Amgen Inc.	Torque driven drug delivery device
AU2018280054B2 (en)	2017-06-08	2023-07-13	Amgen Inc.	Syringe assembly for a drug delivery device and method of assembly
US11541183B2 (en)	2017-06-22	2023-01-03	Amgen Inc.	Device activation impact/shock reduction
US11395880B2 (en)	2017-06-23	2022-07-26	Amgen Inc.	Electronic drug delivery device
EP3651832B1 (en)	2017-07-14	2023-12-13	Amgen Inc.	Needle insertion-retraction system having dual torsion spring system
US11672733B2 (en)	2017-07-21	2023-06-13	Amgen Inc.	Gas permeable sealing member for drug container and methods of assembly
WO2019022950A1 (en)	2017-07-25	2019-01-31	Amgen Inc.	DRUG DELIVERY DEVICE WITH CONTAINER ACCESS SYSTEM AND ASSEMBLY METHOD THEREOF
EP4085942A1 (en)	2017-07-25	2022-11-09	Amgen Inc.	Drug delivery device with gear module and related method of assembly
EP3664863A2 (en)	2017-08-09	2020-06-17	Amgen Inc.	Hydraulic-pneumatic pressurized chamber drug delivery system
EP3668567A1 (en)	2017-08-18	2020-06-24	Amgen Inc.	Wearable injector with sterile adhesive patch
US11103636B2 (en)	2017-08-22	2021-08-31	Amgen Inc.	Needle insertion mechanism for drug delivery device
EP3691717B1 (en)	2017-10-04	2023-02-08	Amgen Inc.	Flow adapter for drug delivery device
WO2019070552A1 (en)	2017-10-06	2019-04-11	Amgen Inc.	DRUG DELIVERY DEVICE COMPRISING A LOCKOUT ASSEMBLY AND ASSOCIATED ASSEMBLY METHOD
MA50348A (fr)	2017-10-09	2020-08-19	Amgen Inc	Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
US11826480B2 (en)	2017-11-03	2023-11-28	Amgen Inc.	Systems and approaches for sterilizing a drug delivery device
WO2019089178A1 (en)	2017-11-06	2019-05-09	Amgen Inc.	Drug delivery device with placement and flow sensing
MA50569A (fr)	2017-11-06	2020-09-16	Amgen Inc	Ensembles de remplissage-finition et procédés associés
MX2020004736A (es)	2017-11-10	2020-08-13	Amgen Inc	Embolos para dispositivos de administracion de farmacos.
SG11202002772VA (en)	2017-11-16	2020-04-29	Amgen Inc	Autoinjector with stall and end point detection
EP3710090A1 (en)	2017-11-16	2020-09-23	Amgen Inc.	Door latch mechanism for drug delivery device
US10835685B2 (en)	2018-05-30	2020-11-17	Amgen Inc.	Thermal spring release mechanism for a drug delivery device
US11083840B2 (en)	2018-06-01	2021-08-10	Amgen Inc.	Modular fluid path assemblies for drug delivery devices
CA3103681A1 (en)	2018-07-24	2020-01-30	Amgen Inc.	Delivery devices for administering drugs
WO2020023336A1 (en)	2018-07-24	2020-01-30	Amgen Inc.	Hybrid drug delivery devices with grip portion
WO2020023220A1 (en)	2018-07-24	2020-01-30	Amgen Inc.	Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
MX2021000749A (es)	2018-07-24	2021-03-29	Amgen Inc	Dispositivos de suministro para administrar farmacos.
EP3829692A1 (en)	2018-07-31	2021-06-09	Amgen Inc.	Fluid path assembly for a drug delivery device
AU2019347710B2 (en)	2018-09-24	2025-05-08	Amgen Inc.	Interventional dosing systems and methods
EP3856283A1 (en)	2018-09-28	2021-08-04	Amgen Inc.	Muscle wire escapement activation assembly for a drug delivery device
WO2020072577A1 (en)	2018-10-02	2020-04-09	Amgen Inc.	Injection systems for drug delivery with internal force transmission
CA3112214A1 (en)	2018-10-05	2020-04-09	Amgen Inc.	Drug delivery device having dose indicator
MX2021002791A (es)	2018-10-15	2021-05-12	Amgen Inc	Proceso de ensamblaje de plataforma para un dispositivo de administracion de farmacos.
US12053617B2 (en)	2018-10-15	2024-08-06	Amgen Inc.	Drug delivery device having damping mechanism
WO2020091956A1 (en)	2018-11-01	2020-05-07	Amgen Inc.	Drug delivery devices with partial drug delivery member retraction
US12485219B2 (en)	2018-11-01	2025-12-02	Amgen Inc.	Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh)	2018-11-01	2024-02-11	美商安進公司	部分針頭縮回之藥物遞送裝置及其操作方法
MX2021012557A (es)	2019-04-24	2021-11-12	Amgen Inc	Conjuntos y metodos de verificacion de esterilizacion de jeringuillas.
MX2022002149A (es)	2019-08-23	2022-03-17	Amgen Inc	Dispositivo de suministro de farmacos con componentes de acoplamiento de capuchon de aguja configurable y metodos relacionados.
BR112023024278A2 (pt)	2021-05-21	2024-01-30	Amgen Inc	Método de otimizar uma receita de enchimento para um recipiente de fármacos

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3691016A (en)	1970-04-17	1972-09-12	Monsanto Co	Process for the preparation of insoluble enzymes
CA1023287A (en)	1972-12-08	1977-12-27	Boehringer Mannheim G.M.B.H.	Process for the preparation of carrier-bound proteins
US3941763A (en)	1975-03-28	1976-03-02	American Home Products Corporation	PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4195128A (en)	1976-05-03	1980-03-25	Bayer Aktiengesellschaft	Polymeric carrier bound ligands
US4330440A (en)	1977-02-08	1982-05-18	Development Finance Corporation Of New Zealand	Activated matrix and method of activation
CA1093991A (en)	1977-02-17	1981-01-20	Hideo Hirohara	Enzyme immobilization with pullulan gel
US4229537A (en)	1978-02-09	1980-10-21	New York University	Preparation of trichloro-s-triazine activated supports for coupling ligands
US4289872A (en)	1979-04-06	1981-09-15	Allied Corporation	Macromolecular highly branched homogeneous compound based on lysine units
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4710473A (en)	1983-08-10	1987-12-01	Amgen, Inc.	DNA plasmids
US4496689A (en) *	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
JP2876058B2 (ja)	1986-08-18	1999-03-31	エミスフィア・テクノロジーズ・インコーポレイテッド	薬物送達システム
US5229490A (en)	1987-05-06	1993-07-20	The Rockefeller University	Multiple antigen peptide system
ATE106249T1 (de)	1987-11-05	1994-06-15	Hybritech Inc	Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik.
US6018026A (en) *	1988-01-22	2000-01-25	Zymogenetics, Inc.	Biologically active dimerized and multimerized polypeptide fusions
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5116964A (en)	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US5225538A (en) *	1989-02-23	1993-07-06	Genentech, Inc.	Lymphocyte homing receptor/immunoglobulin fusion proteins
US5013556A (en)	1989-10-20	1991-05-07	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US5723286A (en)	1990-06-20	1998-03-03	Affymax Technologies N.V.	Peptide library and screening systems
WO1992016192A1 (en)	1991-03-15	1992-10-01	Amgen Inc.	Pulmonary administration of granulocyte colony stimulating factor
US5270170A (en)	1991-10-16	1993-12-14	Affymax Technologies N.V.	Peptide library and screening method
US5733731A (en) *	1991-10-16	1998-03-31	Affymax Technologies N.V.	Peptide library and screening method
CA2118130A1 (en)	1992-04-14	1993-10-28	Jean M. J. Frechet	Dendritic based macromolecules and method of production
US5792451A (en)	1994-03-02	1998-08-11	Emisphere Technologies, Inc.	Oral drug delivery compositions and methods
US5417972A (en) *	1993-08-02	1995-05-23	The Board Of Trustees Of The Leland Stanford Junior University	Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
US5470952A (en)	1993-10-20	1995-11-28	Regeneron Pharmaceuticals, Inc.	CNTF and IL-6 antagonists
US5922545A (en)	1993-10-29	1999-07-13	Affymax Technologies N.V.	In vitro peptide and antibody display libraries
US6309853B1 (en)	1994-08-17	2001-10-30	The Rockfeller University	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
DE4435919C1 (de)	1994-10-07	1995-12-07	Deutsches Krebsforsch	Zinkfinger-DNA, -Protein und ihre Verwendung
US5824784A (en)	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
US5739277A (en)	1995-04-14	1998-04-14	Genentech Inc.	Altered polypeptides with increased half-life
US6096871A (en)	1995-04-14	2000-08-01	Genentech, Inc.	Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6127977A (en)	1996-11-08	2000-10-03	Cohen; Nathan	Microstrip patch antenna with fractal structure
JP4046354B2 (ja)	1996-03-18	2008-02-13	ボードオブリージェンツ，ザユニバーシティオブテキサスシステム	増大した半減期を有する免疫グロブリン様ドメイン
DK0934526T3 (da)	1996-10-08	2003-05-05	Bisys B V U	Fremgangsmåder og midler til udvælgelse af peptider og proteiner, der har specifik affinitet til et mål
US6812327B1 (en) *	1996-10-25	2004-11-02	Human Genome Sciences, Inc.	Neutrokine-alpha polypeptides
EP0939804B2 (en)	1996-10-25	2011-06-15	Human Genome Sciences, Inc.	NEUTROKINE alpha
AU5705898A (en)	1996-12-17	1998-07-15	Schering Corporation	Mammalian cell surface antigens; related reagents
US5969102A (en)	1997-03-03	1999-10-19	St. Jude Children's Research Hospital	Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en)	1997-04-02	1998-10-02	Smithkline Beecham Corporation	A tnf homologue, tl5
WO1998055621A1 (en)	1997-06-06	1998-12-10	Regeneron Pharmaceuticals, Inc.	Ntn-2 member of tnf ligand family
WO1998055620A1 (en)	1997-06-06	1998-12-10	Regeneron Pharmaceuticals, Inc.	Ntn-2 member of tnf ligand family
WO1999011791A2 (en)	1997-09-05	1999-03-11	University Of Washington	Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
TR200000654T2 (tr)	1997-09-12	2000-07-21	Apotech R & D Sa	KAY-Yeni bir bağışıklık sistemi proteini.
AU2212299A (en)	1998-01-05	1999-07-26	Genentech Inc.	Compositions and methods for the treatment of tumor
WO1999062951A1 (en) *	1998-06-04	1999-12-09	Shanghai Second Medical University	A human zinc finger protein gene (bmzf3)
US6660843B1 (en)	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
DK1642973T3 (da)	1999-01-07	2009-11-02	Zymogenetics Inc	Terapeutisk anvendelser af BR43X2-oplöselige receptorer
EP1415659B9 (en) *	1999-01-25	2012-02-15	Biogen Idec MA Inc.	An antibody specific for soluble BAFF for use in the treatment of cancer
US20030095967A1 (en) *	1999-01-25	2003-05-22	Mackay Fabienne	BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
AU2880400A (en)	1999-02-12	2000-08-29	Amgen, Inc.	Tnf-related proteins
US20030022233A1 (en)	1999-04-30	2003-01-30	Raymond G. Goodwin	Methods of use of the taci/taci-l interaction
US6475987B1 (en)	1999-05-06	2002-11-05	National Jewish Medical And Research Center	Tall-1 receptor homologues
WO2001002440A1 (en)	1999-07-02	2001-01-11	Genentech, Inc.	Fusion peptides comprising a peptide ligand domain and a multimerization domain
EP1254227A2 (en)	2000-02-11	2002-11-06	Amgen Inc.	Fusion receptor from tnf family
DE60140773D1 (de) *	2000-08-18	2010-01-21	Dyax Corp	Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS)
WO2002016411A2 (en)	2000-08-18	2002-02-28	Human Genome Sciences, Inc.	Binding polypeptides and methods based thereon
CN1970077A (zh) *	2001-05-11	2007-05-30	安姆根有限公司	与tall－1结合的肽和相关分子
AR035119A1 (es) *	2001-08-16	2004-04-14	Lilly Co Eli	Anticuerpos humanos antagonistas anti-htnfsf13b
MXPA05007019A (es) *	2002-12-30	2005-08-18	Amgen Inc	Terapia de combinacion con factores co-estimuladores.
CA2572765C (en) *	2004-07-08	2013-05-21	Amgen Inc.	Compound having improved bioefficiency when administered in a multidose regimen
US8008453B2 (en) *	2005-08-12	2011-08-30	Amgen Inc.	Modified Fc molecules
KR101104556B1 (ko)	2006-12-05	2012-01-11	가부시키가이샤 고베 세이코쇼	인쇄판용 고강도 알루미늄 합금판
PH12022550138A1 (en) *	2013-03-13	2023-03-06	Amgen Inc	Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) *	2013-03-13	2016-10-04	Amgen Inc.	Proteins specific for BAFF and B7RP1
WO2020175345A1 (ja)	2019-02-27	2020-09-03	株式会社村田製作所	コネクタ、コネクタセット

2002
- 2002-05-13 CN CNA2006101537090A patent/CN1970077A/zh active Pending
- 2002-05-13 SK SK1489-2003A patent/SK288175B6/sk not_active IP Right Cessation
- 2002-05-13 KR KR1020037014672A patent/KR100902687B1/ko not_active Expired - Fee Related
- 2002-05-13 MX MXPA03010210A patent/MXPA03010210A/es active IP Right Grant
- 2002-05-13 JP JP2002589503A patent/JP4516719B2/ja not_active Expired - Lifetime
- 2002-05-13 DE DE60222882T patent/DE60222882T2/de not_active Expired - Lifetime
- 2002-05-13 CA CA2446189A patent/CA2446189C/en not_active Expired - Fee Related
- 2002-05-13 CZ CZ2003-3291A patent/CZ304592B6/cs not_active IP Right Cessation
- 2002-05-13 EP EP20100178373 patent/EP2292655B1/en not_active Expired - Lifetime
- 2002-05-13 CN CNB028140095A patent/CN100448891C/zh not_active Expired - Fee Related
- 2002-05-13 BR BR0209546-7A patent/BR0209546A/pt not_active Application Discontinuation
- 2002-05-13 EP EP20070019762 patent/EP1921088B1/en not_active Expired - Lifetime
- 2002-05-13 DK DK02769739T patent/DK1385882T3/da active
- 2002-05-13 NZ NZ529267A patent/NZ529267A/en not_active IP Right Cessation
- 2002-05-13 AT AT10178373T patent/ATE549354T1/de active
- 2002-05-13 EP EP02769739A patent/EP1385882B9/en not_active Expired - Lifetime
- 2002-05-13 EA EA200301241A patent/EA010435B1/ru not_active IP Right Cessation
- 2002-05-13 ES ES10178373T patent/ES2387546T3/es not_active Expired - Lifetime
- 2002-05-13 SI SI200230645T patent/SI1385882T1/sl unknown
- 2002-05-13 US US10/145,206 patent/US7259137B2/en not_active Expired - Lifetime
- 2002-05-13 RS YU95203A patent/RS51708B/sr unknown
- 2002-05-13 ES ES02769739T patent/ES2295404T3/es not_active Expired - Lifetime
- 2002-05-13 IL IL15871902A patent/IL158719A0/xx unknown
- 2002-05-13 PL PL39331702A patent/PL393317A1/pl unknown
- 2002-05-13 PT PT02769739T patent/PT1385882E/pt unknown
- 2002-05-13 ES ES07019762.9T patent/ES2527471T3/es not_active Expired - Lifetime
- 2002-05-13 EP EP14180109.2A patent/EP2845864A3/en not_active Withdrawn
- 2002-05-13 EE EEP200300552A patent/EE05294B1/xx not_active IP Right Cessation
- 2002-05-13 AU AU2002342669A patent/AU2002342669C1/en not_active Ceased
- 2002-05-13 PL PL369570A patent/PL210546B1/pl unknown
- 2002-05-13 WO PCT/US2002/015273 patent/WO2002092620A2/en not_active Ceased
- 2002-05-13 CN CNA2006101537137A patent/CN1970078A/zh active Pending
- 2002-05-13 NZ NZ542878A patent/NZ542878A/en not_active IP Right Cessation
- 2002-05-13 AT AT02769739T patent/ATE375361T1/de active
- 2002-05-13 HU HU0700125A patent/HU229910B1/hu not_active IP Right Cessation
2003
- 2003-10-31 ZA ZA200308513A patent/ZA200308513B/en unknown
- 2003-11-02 IL IL158719A patent/IL158719A/en not_active IP Right Cessation
- 2003-11-10 NO NO20034980A patent/NO331785B1/no not_active IP Right Cessation
- 2003-11-12 BG BG108349A patent/BG66270B1/bg unknown
2005
- 2005-11-10 US US11/272,521 patent/US7737111B2/en not_active Expired - Fee Related
2008
- 2008-01-09 CY CY081100030T patent/CY1107131T1/el unknown
2010
- 2010-05-26 US US12/788,137 patent/US8507426B2/en not_active Expired - Fee Related
2013
- 2013-07-09 US US13/938,141 patent/US9139645B2/en not_active Expired - Fee Related
2015
- 2015-08-21 HK HK15108146.9A patent/HK1207390A1/en unknown
- 2015-09-21 US US14/860,381 patent/US20160176926A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CZ20033291A3 (cs)	2004-11-10
EP1385882B1 (en)	2007-10-10
US7259137B2 (en)	2007-08-21
ATE549354T1 (de)	2012-03-15
US20160176926A1 (en)	2016-06-23
NO20034980D0 (no)	2003-11-10
WO2002092620A2 (en)	2002-11-21
EA200301241A1 (ru)	2004-08-26
HUP0700125A2 (en)	2007-06-28
AU2002342669C1 (en)	2010-10-07
US9139645B2 (en)	2015-09-22
ES2387546T3 (es)	2012-09-25
SI1385882T1 (sl)	2008-04-30
ZA200308513B (en)	2004-09-16
MXPA03010210A (es)	2004-03-10
EP1921088B1 (en)	2014-10-08
PL393317A1 (pl)	2011-05-23
BR0209546A (pt)	2004-06-29
NZ542878A (en)	2007-06-29
JP4516719B2 (ja)	2010-08-04
BG108349A (bg)	2004-11-30
NO331785B1 (no)	2012-03-26
DE60222882D1 (de)	2007-11-22
US20100240590A1 (en)	2010-09-23
EP1385882A4 (en)	2005-09-21
YU95203A (sh)	2006-05-25
CA2446189A1 (en)	2002-11-21
ATE375361T1 (de)	2007-10-15
SK288175B6 (sk)	2014-04-02
PL210546B1 (pl)	2012-01-31
US20060135431A1 (en)	2006-06-22
HUP0700125A3 (en)	2010-01-28
PT1385882E (pt)	2008-01-11
HU229910B1 (hu)	2014-12-29
CZ304592B6 (cs)	2014-07-23
WO2002092620A3 (en)	2003-08-21
IL158719A0 (en)	2004-05-12
DK1385882T3 (da)	2008-02-11
HK1207390A1 (en)	2016-01-29
CN1535281A (zh)	2004-10-06
KR100902687B1 (ko)	2009-06-15
AU2002342669B2 (en)	2005-09-22
US8507426B2 (en)	2013-08-13
US7737111B2 (en)	2010-06-15
EA010435B1 (ru)	2008-08-29
EP1921088A2 (en)	2008-05-14
US20030195156A1 (en)	2003-10-16
EP1921088A3 (en)	2009-01-14
NO20034980L (no)	2003-12-12
PL369570A1 (en)	2005-05-02
CY1107131T1 (el)	2012-10-24
IL158719A (en)	2013-09-30
EP2292655A1 (en)	2011-03-09
EP2845864A2 (en)	2015-03-11
BG66270B1 (bg)	2012-11-30
SK14892003A3 (en)	2004-11-03
HK1059269A1 (en)	2004-06-25
ES2527471T3 (es)	2015-01-26
ES2295404T3 (es)	2008-04-16
CN100448891C (zh)	2009-01-07
CA2446189C (en)	2011-10-18
EP2845864A3 (en)	2015-06-10
NZ529267A (en)	2006-05-26
RS51708B (sr)	2011-10-31
EP1385882A2 (en)	2004-02-04
EP2292655B1 (en)	2012-03-14
KR20040012815A (ko)	2004-02-11
CN1970077A (zh)	2007-05-30
CN1970078A (zh)	2007-05-30
JP2004533249A (ja)	2004-11-04
US20140234334A1 (en)	2014-08-21
HK1151545A1 (en)	2012-02-03
EE200300552A (et)	2004-02-16
EP1385882B9 (en)	2009-08-12
DE60222882T2 (de)	2008-07-10

Publication	Publication Date	Title
EE05294B1 (et)	2010-04-15	TALL-1-ga seostuv ainekompositsioon
DE60321847D1 (de)	2008-08-14	Hydrogel-Klebstoffe zur Verwendung auf Fasern besetzten Oberflächen
AU5169693A (en)	1994-07-04	Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists
PL330952A1 (en)	1999-08-02	Composition having antimicrobial properties and method of disinfecting surfaces
ID18883A (id)	1998-05-20	Pesaing 5-ht 1f
DE59703471D1 (de)	2001-06-07	Betain-geminitenside auf der basis von aminen
ATE170194T1 (de)	1998-09-15	Neue inklusionskomplexe von salzen von nimesulide mit cyclodextrinen
BRPI0416106A (pt)	2007-01-02	ácidos 4 -((fenoxialquil)tio)-fenoxiacéticos e análogos
ATE187461T1 (de)	1999-12-15	Cyklopeptolide
WO2003029895A8 (de)	2003-11-20	Effiziente nichtlinear-optische polymere mit hoher polungsstabilität
ATE162844T1 (de)	1998-02-15	Beschichtungsmittel mit wärmehärtender filmbildung und dessen verwendung
ATE275964T1 (de)	2004-10-15	Verwendung von betalycan zur verminderung der narbenbildung
EP1067138A4 (en)	2004-11-03	HYDROXYPROLINE DERIVATIVES
TR199902815T2 (xx)	2000-08-21	Anksiyete ve gerginlik tedavisinde 1-ar(alk) ilimidazolin-2-tek kullan�m�
ATE190316T1 (de)	2000-03-15	Peptid-aldehydderivate als antikoagulierende mittel
AU2002315612A1 (en)	2003-03-03	Fragrance and flavour compositions
AU2002251873A1 (en)	2002-08-19	Methods and compositions for modulating gluconeogenesis using pgc-1
DE60203726D1 (de)	2005-05-19	Topische zusammensetzung enthaltend brucin und ihre verwendung zur behandlung von hautschäden
AR009282A1 (es)	2000-04-12	Inhibidores moleculares de adhesion celular mediados por integrina beta2
EP0928792A3 (en)	2001-06-27	Bicyclic(3.1.0)hexanes and related compounds
GT199400074A (es)	1996-05-07	Pirroles substituidos

Legal Events

Date	Code	Title	Description
2010-02-15	HK1A	Erratum in gazette
2011-02-15	KB4A	Valid patent at the end of a year	Effective date: 20101231
2020-12-15	MM4A	Lapsed by not paying the annual fees	Effective date: 20200513